SLC12A5 and spinal cord injury: To achieve this, key pathways are blocked/activated by pharmacological means, such as the P2X4-BDNF-KCC2 pathway (Ferrini et al., 2013; Romeo-Guitart and Casas, 2020), BDNF-trkb (Miletic and Miletic, 2008; Rivera et al., 2002; Rivera et al., 2004; Huang et al., 2017; Wenner, 2014; Sánchez-Brualla et al., 2018) or direct regulation of KCC2 activity, such as N and C termin (Ferrini et al., 2013) N-terminal loop Chi et al., 2021, phosphorylation of serine 940 (Leonzino et al., 2016) will likely be potential targets for clinical treatment of spinal cord injury and its complications.